During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Onvansertib Receives FDA Orphan Drug Designation for CMML
2
Severe Toxicities Rare After Lifileucel in Advanced Melanoma
3
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
4
Male Sex, Age, and Tumor Genetics Linked to Thyroid Cancer Mortality
5